Efficacy and Safety of Intravenous Monoclonal Antibodies in Patients with Moderate-to-severe Active Graves'ophthalmopathy: a Systematic Review and Meta-analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Jun 8

PMID 37288301

Authors

Yu Hu

Jinhua Chen

Ken Lin

XiJie Yu

Affiliations

Soon will be listed here.

Abstract

Backgrounds: The effects of various treatments on Graves' ophthalmopathy (GO) have been studied. As monoclonal antibodies (mAbs) have been proposed for the treatment of moderate to severe GO, direct comparisons between different mAbs are lacking.We therefore conducted this meta-analysis to objectively compare the efficacy and safety of intravenous mAbs.

Methods: To identify eligible trials, references published before September 2022 were electronically searched in PubMed, Web of Science, Pubmed, Embase,Cochrane Library, CBM, CNKI,Wan-Fang and ICTRP databases.The Newcastle-Ottawa scale (NOS) and the Cochrane Risk of Bias Assessment Tool were used to assess the risk of bias of the original studies.The primary and secondary outcomes were the response and inactivation rates, with the secondary outcomes being the clinical activity score (CAS),the improvement of proptosis and diplopia improvement,and the adverse event rate. Publication bias was evaluated, along with subgroup and sensitivity analyses.

Results: A total of 12 trials with 448 patients were included. The meta-analysis showed that TCZ (tocilizumab) was most likely to be the best treatment in terms of response according to indirect contrast, followed by TMB (teprotumumab) and RTX (rituximab).TCZ, followed by TMB and RTX, was also most likely to be the best treatment in terms of reducing proptosis. In terms of improving diplopia, TMB was most likely to be the best treatment, followed by TCZ and RTX.TCZ was the highest probability of safety, followed by RTX and TMB.

Conclusions: Based on the best available evidence,TCZ should be the preferred treatment for moderate to severe GO.In the absence of head-to-head trials,indirect comparisons of treatments are routinely used to estimate the effectiveness of the treatments of interest. In addition,the optimal dose and potential mechanism of action of monoclonal antibodies remain to be established,and it is encouraging that the treatment paradigm for GO may change in the future.This study was designed in accordance with the Preferred Reporting Items for conducting Systematic Reviews and Meta-Analyses (PRISMA)(27).

Systematic Review Registration: http://www.crd.york.ac.uk/prospero, identifier CRD42023398170.

Citing Articles

Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment.

Huang J, Su A, Yang J, Zhuang W, Li Sr Z J Clin Endocrinol Metab. 2024; 110(1):159-165.

PMID: 38878281 PMC: 11651674. DOI: 10.1210/clinem/dgae417.

Commentary: Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves' ophthalmopathy: a systematic review and meta-analysis.

Li L, Wu J Front Endocrinol (Lausanne). 2024; 15:1394616.

PMID: 38863931 PMC: 11165054. DOI: 10.3389/fendo.2024.1394616.

Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets.

Cieplinska K, Niedziela E, Kowalska A J Clin Med. 2024; 13(1).

PMID: 38202079 PMC: 10780108. DOI: 10.3390/jcm13010072.

References

Deltour J, dAssigny Flamen M, Ladsous M, Giovansili L, Cariou B, Caron P . Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol. 2020; 258(9):2013-2021. DOI: 10.1007/s00417-020-04651-6. View

Fallahi P, Ferrari S, Ragusa F, Ruffilli I, Elia G, Paparo S . Th1 Chemokines in Autoimmune Endocrine Disorders. J Clin Endocrinol Metab. 2019; 105(4). DOI: 10.1210/clinem/dgz289. View

Emery P, Keystone E, Tony H, Cantagrel A, Vollenhoven R, Sanchez A . IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67(11):1516-23. PMC: 3811149. DOI: 10.1136/ard.2008.092932. View

Supronik J, Szelachowska M, Kretowski A, Siewko K . Rituximab in the treatment of Graves' orbitopathy: latest updates and perspectives. Endocr Connect. 2022; 11(12). PMC: 9716394. DOI: 10.1530/EC-22-0303. View

Rapoport B, McLachlan S . Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab. 2014; 99(11):4060-1. PMC: 4223433. DOI: 10.1210/jc.2014-3011. View

BASCHIERI L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R . Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid. 1997; 7(4):579-85. DOI: 10.1089/thy.1997.7.579. View

Chin Y, Ng C, Lee M, Koh J, Kiew J, Yang S . Prevalence of thyroid eye disease in Graves' disease: A meta-analysis and systematic review. Clin Endocrinol (Oxf). 2020; 93(4):363-374. DOI: 10.1111/cen.14296. View

Paik J, Kim S, Kim J, Lee J, Yang S, Lee S . Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy. Immunobiology. 2020; 225(2):151902. DOI: 10.1016/j.imbio.2019.151902. View

Ugradar S, Goldberg R, Rootman D . Bony Orbital Volume Expansion in Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2018; 35(5):434-437. DOI: 10.1097/IOP.0000000000001292. View

10.

Wichary H, Gasinska T . Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy. Thyroid. 2011; 22(1):64-9. DOI: 10.1089/thy.2010.0158. View

11.

Hunter C, Jones S . Corrigendum: IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2017; 18(11):1271. DOI: 10.1038/ni1117-1271b. View

12.

Pritchard J, Han R, Horst N, Cruikshank W, Smith T . Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003; 170(12):6348-54. DOI: 10.4049/jimmunol.170.12.6348. View

13.

Smith T . The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy. Eye (Lond). 2018; 33(2):200-205. PMC: 6367397. DOI: 10.1038/s41433-018-0265-2. View

14.

Smith T, Kahaly G, Ezra D, Fleming J, Dailey R, Tang R . Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017; 376(18):1748-1761. PMC: 5718164. DOI: 10.1056/NEJMoa1614949. View

15.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

16.

Kotwal A, Stan M . Thyrotropin Receptor Antibodies-An Overview. Ophthalmic Plast Reconstr Surg. 2018; 34(4S Suppl 1):S20-S27. DOI: 10.1097/IOP.0000000000001052. View

17.

Gerding M, Terwee C, Dekker F, Koornneef L, Prummel M, Wiersinga W . Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1998; 7(6):885-9. DOI: 10.1089/thy.1997.7.885. View

18.

Tanda M, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L . Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013; 98(4):1443-9. DOI: 10.1210/jc.2012-3873. View

19.

Douglas R, Kahaly G, Ugradar S, Elflein H, Ponto K, Fowler B . Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Ophthalmology. 2021; 129(4):438-449. DOI: 10.1016/j.ophtha.2021.10.017. View

20.

Salvi M, Vannucchi G, Curro N, Campi I, Covelli D, Dazzi D . Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2014; 100(2):422-31. PMC: 4318899. DOI: 10.1210/jc.2014-3014. View